A strategic level partnering event with a wide range of drug delivery technologies

5TH ANNUAL
PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

OCTOBER 5 - 6, 2015    INTERCONTINENTAL BOSTON, BOSTON, MA

KEYNOTE
Robert Langer, PhD
MIT

KEYNOTE
Bahija Jallal, PhD
AstraZeneca

KEYNOTE
Stéphane Bancel
Moderna Therapeutics

CHAIR
Barbara Lueckel, PhD
Roche

NON-INJECTABLES CHAIR
Fernando Sallés, PhD
Teva Pharmaceuticals

INJECTABLES CHAIR
Matthew Burke, PhD
GSK

DEVICES CHAIR
Tomas Landh, PhD
Novo Nordisk

Follow us on Twitter @ConferenceForum #PODD2015

REGISTER at www.theconferenceforum.org or CALL 646-350-2580
OVERVIEW

The Conference Forum is delighted to present the 5th Annual PODD, Partnership Opportunities in Drug Delivery event. This annual Boston-based conference is designed with three purposes:

1. To present a strategic level program for pharma and biotech business development professionals with a thorough overview of the latest drug delivery technologies available, along with an update on deals and opportunities to improve therapies and extend the life cycle of a drug.

2. To provide drug delivery and specialty pharmas with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.

3. To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones.

The 5th annual event is chaired by Barbara Lueckel, PhD, Global Business Development Director, Roche and keynoted by Robert Langer, PhD, David H.Koch Institute Professor, MIT, Bahija Jallal, PhD, EVP, MedImmune AstraZeneca and Stéphane Bancel, CEO, Moderna Therapeutics.

The ultimate goal for PODD is to foster a meeting place that inspires innovation and advancement of drug development and delivery as well as providing support for the leaders behind the movement.

Sincerely,

Michelle McDermott
Conference Producer

Valerie Bowling
Executive Director

Jessica Rothenberg
Marketing Director

Meredith Sands
Executive Director, Business Development

Omaima Khan
Conference Coordinator

SPEAKING FACULTY

PJ Anand
Founder, President & CEO
Alcyone Lifesciences

Jessica Ballinger
Senior Director, Protein Pharmaceutical Development
Biogen Idec

Stéphane Bancel
CEO
Moderna Therapeutics

Vahe Bedian, PhD
Director, Search and Evaluation, Global Product and Portfolio Strategy
AstraZeneca

Matthew Burke, PhD
Head of Drug Delivery, Global Formulations, RD Platform Technology & Science
GSK

Bob Brown, PhD
CSO, SVP Research
Dicerna Pharmaceuticals

Christopher Coletta, PhD
Director, Drug Delivery Strategy & Innovation
Amgen

Abla Creasey, PhD
Senior Scientific Director, Primary Container & Drug Delivery Systems/PDMS
Janssen
SPEAKING FACULTY

James Cunningham, PhD
Director, Ocular Drug Delivery
Allergan

Ann Daugherty, PhD
Senior Manager, Drug Delivery
Genentech

Paul DeAngelis, PhD
Chief Scientist
Caisson Biotech

Tom DePaul
VP, Sales & Marketing
PharmaCircle

Ann DeWitt, PhD
Senior Director of Investments
Sanofi-Genzyme BioVentures

Omid Farokhzad, MD
Associate Professor
Harvard Medical School

Michael Graffeo
VP, Business Development, Drug Delivery
Insulet Corporation

Kapil Gupta, PhD
Principal Scientist and Group Leader, Protein Pharmaceutical and Device Development
Biogen

David Haase
Senior Manager, Device Development
Genentech

Andrew Hamer, MD
VP, Medical Affairs
Capricor Therapeutics

Justin Hanes, PhD
Lewis J. Ort Professor, Director, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine

Michael Hooven
President and CEO
Enable Injections

Bahija Jallal, PhD
EVP, MedImmune
AstraZeneca

Paul Jansen
VP, Medical Device Development
Sanofi

Yalia Jayalakshmi (Jaya), PhD
Senior Director, Drug Delivery Technologies
Onyx Pharmaceutical

Viral Kansara, PhD
Investigator and Head of Ocular Pharmacokinetic and Drug Delivery Lab
Novartis Institutes for Biomedical Research

Tugrul Kararli, PhD, MBA
President and Founder
PharmaCircle

Jörg Kaufman, PhD
Chief Scientific Officer
Silence Therapeutics

Richard Korsmeyer, PhD
Executive Director, Advanced External Projects, Pharmaceutical Sciences
Pfizer

Tomas Landh, PhD
Director, Strategy & Sourcing, Diabetes Research Unit
Novo Nordisk

Robert Langer, PhD
David H. Koch Institute Professor
MIT

Andrew Lewis, PhD
Director, Novel Drug Delivery Technologies, CMC & E Peptides
Ipsen

Philippe Lopes-Fernandes
SVP, Head of Global Licensing & Business Development
Merck Serono / EMD Serono

Barbara Lueckel, PhD
Head of Research & Technologies Partnering
Roche

Muthiah (Mano) Manoharan, PhD
Senior VP, Drug Discovery
Alnylam Pharmaceuticals

Vijendra Nalamothu, PhD
Co-Founder and CEO
Tergus Pharma

REGISTER at WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580
5TH ANNUAL PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

AGENDA

DENIS PATRICK
Executive Director, Head External R&D Innovation,
Oncology Research Unit
Pfizer

DIVAKAR RAMAKRISHNAN, PHD
VP, Drug Delivery/Device R&D and Strategy
Eli Lilly

JULIA RASHBA-STEP, PHD
Senior Director, Novel Delivery Technologies
Pfizer BioTherapeutics

DAVID ROZEMA
VP, Chemistry
Arrowhead Research

FERNANDO SALLÉS, PHD
VP, Head of Global Search
Teva Pharmaceuticals

JAYMIN SHAH, PHD
Research Fellow
Pfizer

IAIN SIMPSON
Associate Director, Drug Delivery
Cambridge Consultants

ANAND SUBRAMONY, PHD
VP, Drug Delivery & Device Development
MedImmune

MARK TOMAI, PHD
Head of TLR and MRS Business Development
3M Drug Delivery Systems

BRECA TRACY, PHD
VP and Managing Director
Caisson Biotech

ROB VEASEY
Senior Sector Manager, Medical and Scientific
DCA Design International

ANDRE WATSON
Chief Technical Officer
Ligandal

BILL WELCH
Chief Technology Officer
Phillips Medisize

STEPHEN YOO, MD
Chief Medical Officer
REGENXBIO

DAY ONE - MONDAY, OCTOBER 5, 2015

8:00 am
Breakfast & Registration
Hosted by:

8:45 am
Chair's Opening Remarks
Barbara Lueckel, PhD
Head of Research & Technologies Partnering, Roche

9:00 am
Opening Keynote Address on Nanotechnology
Robert Langer, PhD
Koch Institute Professor, MIT

9:50 am
Keynote: Enabling Patient Centric Therapies through Innovation in Personalized Healthcare and Drug Delivery
Bahija Jallal, PhD
EVP, AstraZeneca, Head of MedImmune

We are delighted to welcome our 2015 industry keynote, Dr Bahija Jallal, EVP, MedImmune. Dr Jallal is responsible for biologics research, development and clinical activities. As part of AstraZeneca’s Senior Executive Team, she is tasked with advancing the biologic organization’s pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardiovascular and gastrointestinal disorders and pain. Joining Dr Jallal on the stage is PODD veteran, Dr Anand Subramony, VP, Drug Delivery & Device Development, MedImmune. Together, they will speak on the following.

Drug delivery and connected health technologies will deliver patient centric therapeutics and will transform how patients manage their health in the near future. As personalized health care strategies and companion diagnostics become reality, pharmaceutical and biotech companies are shifting to a “patient outcome”, or ‘pay for value’ based model. Pharma models are therefore evolving toward creating total solutions for patients rather than simply acting as a provider of dosage forms. Drug delivery plays an important role in this new paradigm. The emergence of biologics have led to the development of novel devices for parenteral delivery and has redefined the need for novel drug delivery technologies for biologics.

Bahija Jallal, PhD
EVP, AstraZeneca, Head of MedImmune
AGENDA

5TH ANNUAL PARTNERSHIP OPPORTUNITIES IN DRUG DELIVERY

with

Anand Subramony, PhD
VP, Drug Delivery & Device Development, MedImmune

10:30 am
Networking Break & Partnering Meetings

11:15 am
Licensing Drug Delivery Technologies for Oncology Therapeutics
In this panel, we will hear from business development and licensing executives regarding current level of interest in drug delivery technologies for pipeline and launched drugs.

- Licensing improved formulations of off-patent cancer drugs vs. enabling platform technologies for NCEs
- Criteria used to evaluate novel oncology drug delivery systems
- What stage and type of data is most attractive to pharmaceutical partners?
- Types of formulations and technology platforms actively sought:
  - Nanotechnology-based/Nanomedicine
  - Antibody drug conjugates
  - Sustained release depots/implants
- Structuring partnerships – platform vs. product licenses, option-based agreements, regional deals

Moderator:
Barbara Lueckel, PhD
Head of Research & Technologies Partnering, Roche

Panelists:
PJ Anand
Founder, President & CEO, Alcyone Lifesciences

Vahe Bedian, PhD
Director, Search and Evaluation, Global Product and Portfolio Strategy, AstraZeneca

Yalia Jayalakshmi (Jaya), PhD
Senior Director, Drug Delivery Technologies, Onyx Pharmaceutical

Philippe Lopes-Fernandes
SVP, Head of Global Licensing & Business Development, Merck Serono / EMD Serono

Denis Patrick, PhD
Executive Director, Head External R&D Innovation, Oncology Research Unit, Pfizer

12:00 pm
The SoloStar Injection Device: Foundation for a Versatile Platform
Paul Jansen
VP, Medical Device Development, Sanofi

Rob Veasey
Senior Sector Manager, Medical and Scientific, DCA Design International

Bill Welch
Chief Technology Officer, Phillips-Medisize Corporation

12:40 pm
A Year in Review in Drug Delivery: A PharmaCircle Perspective
Tugrul Kararli, PhD, MBA
President and Founder, PharmaCircle

12:55 pm
Luncheon & Partnering Meetings

2:15 pm
Drug Delivery Presentations in Three Tracks

Track One – Non-Injectable Formulation Technologies
Chaired by:
Fernando Sallés, PhD
VP, Head of Global Search, Teva Pharmaceuticals

- Altus Formulation
- Lucideon
- Nanologica
- Salvona
- Tergus Pharma
- ViSci

Track Two – Injectable Formulation Technologies
Chaired by:
Matthew Burke, PhD
Head of Drug Delivery, Global Formulations, RD Platform Technology & Science, GSK

- Althea
- Bioasis
- Caisson Biotech
- Ceramisphere
- Enable
- Genisphere
Innocore
Novozymes
Sensile
Starpharma

Track Three – Drug Delivery Device Technologies
Chaired by:
Tomas Landh, PhD
VP, Innovation Sourcing, Novo Nordisk

• 3M
• Balda
• Bio-corp
• Credence
• Delta Mod Tech
• Insulet
• Medpharm
• Mercator Systems
• Oval Medical
• Nemera
• PKA SoftTouch
• Salvona
• Unilife
• Vectura

There will be a 15-minute break at 4:00 pm.

If you are interested in presenting in one of the tracks, please contact Meredith Sands at Meredith@tcfllc.org.

6:00 pm
Day One Concludes

DAY TWO - TUESDAY, OCTOBER 6, 2015

8:00 am
Breakfast & Partnering Meetings
Hosted by:

8:30 am
Chair’s Welcome
Barbara Lueckel, PhD
Head of Research & Technologies Partnering, Roche

8:45 am
How We Built Moderna
Stéphane Bancel joined Moderna in 2011 when it had one employee and patent and has assembled a company pioneering in the development of messenger RNA (mRNA) Therapeutics. It was recently named the #1 Disruptor on the third-annual CNBC Disruptor 50 list. For the second year in a row, CNBC recognizes Moderna as one of the country’s most ambitious and innovative companies changing the economy and overall business landscape.

Stéphane Bancel
CEO, Moderna Therapeutics

9:30 am
Utilizing Nanotechnology to Advance Targeted Therapies and Personalized Medicine
Moderator:
Omid Farokhzad, MD
Associate Professor, Harvard Medical School

10:15 am
Networking Break & Partnering Meetings

11:00 am
Technology Spotlight
Sponsored by:

11:20 am
Large Volume Drug Delivery – Are Patch Pumps the Answer?
Due to the increasing need for improved parenteral delivery of high dose pharmaceuticals, especially biologics,
a number of new wearable devices have been developed, such as patch pumps and bolus injectors. These devices enable self-administration and eliminate the need for multiple injections or infusions. This panel will discuss the current generation of wearable injection devices and the opportunities and challenges that lie ahead.

- Key drawbacks of current devices – what should next generation devices address?
- Beyond insulin, will patch pumps be cost-effective for other drugs such as mAbs?
- How does the size of the device affect patient acceptability?
- Implementing acceptance of wearable technology
- Selecting the appropriate device, and device manufacturer-partner

Moderator:
**Christopher Coletta, PhD**  
Director, Drug Delivery Strategy & Innovation, Amgen

Panelists:
- **Michael Graffeo**  
  VP, Business Development, Drug Delivery, Insulet Corporation
- **David Haase**  
  Senior Manager, Device Development, Genentech
- **Andrew Hamer, MD**  
  VP, Medical Affairs, Capricor Therapeutics
- **Michael Hooven**  
  President and CEO, Enable Injections
- **Iain Simpson**  
  Associate Director, Drug Delivery, Cambridge Consultants
- **Anand Subramony, PhD**  
  VP, Drug Delivery & Device Development, MedImmune

12:00 pm  
**Fifth Annual Company Spotlights**

In this session, we highlight three companies that discuss their partnering philosophy, current needs and scouting interests as related to drug delivery.

**Amgen**  
Christopher Coletta, PhD  
Director of Drug Delivery Strategy & Innovation

**Sanofi-Genzyme BioVentures**  
Ann DeWitt, PhD  
Senior Director of Investments

**Janssen**  
Abla Creasey, PhD  
Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences

**Eli Lilly**  
Divakar Ramakrishnan, PhD  
VP, Drug Delivery/Device R&D and Strategy

1:00 pm  
**Luncheon, Roundtable and Partnering Meetings**

The PODD Luncheon Roundtables are open to all delegates and feature a dedicated moderator with expertise in a particular area. The PODD Roundtables are an excellent way to engage in in-depth discussions and meet colleagues with similar interests. Grab your lunch and choose to join an optional round table or attend partnering meetings.

Sponsored by:

**Biogen**

**Brain Delivery of Large Molecules**

Moderator:
Kapil Gupta, PhD  
Principal Scientist and Group Leader, Protein Pharmaceutical and Device Development, Biogen

**Delivery Strategies for Orphan CNS Diseases**

Moderator:
PJ Anand  
Founder, President and CEO, Alcyone Lifesciences

**Special Considerations in Topical Formulation for Proteins and Peptides**

Moderator:
Vijendra Nalamothu, PhD  
Co-Founder and CEO, Tergus Pharma

**Oral Peptide Delivery**

Moderator:
Andrew Lewis, PhD  
Director Novel Drug Delivery Technologies, CMC & E Peptides, Ipsen
2:00 pm
Can RNA-based Therapeutics Really Deliver?

Despite the therapeutic promise of RNA therapeutics, efficient and safe drug delivery remains a significant challenge. These therapeutics tend to have unfavorable physicochemical properties including negative charges, large molecular weight and size, and instability. A number of carrier systems are being developed for RNA therapeutics, including polymers, lipids, and conjugates, but selection of the delivery system depends on the therapeutics properties, type of target cells and the desired delivery route. This panel will discuss:

- Key hurdles related to delivery of RNA therapeutics: siRNA, mRNA, RNAi
- Delivery strategies and examples of recent successes
- Collaborative approaches/models that are working
- Commercialization prospects given low success rate of RNA drugs to-date

Moderator:
Jessica Ballinger
Senior Director, Protein Pharmaceutical Development, Biogen Idec

Panelists:
Bob Brown, PhD
CSO, SVP Research, Dicerna Pharmaceuticals

Abla Creasey, PhD
Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences, Janssen

Jörg Kaufmann, PhD
Chief Scientific Officer, Silence Therapeutics

Muthiah (Mano) Manoharan, PhD
Senior VP, Drug Discovery, Alnylam Pharmaceuticals

Dave Rozema
VP, Chemistry, Arrowhead Research

2:45 pm
DDS Technology Soapbox@PODD sponsored by Pfizer

This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

Moderator:
Julia Rashba-Step, PhD
Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

If you are interested in presenting on the Soapbox, please contact Meredith Sands at Meredith@tcflc.org.

3:45 pm
Improving Drug Delivery to the Back of the Eye

There is an increasing need to successfully treat posterior eye diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy. Drug delivery to the back of the eye is challenging not only because of the anatomy of the eye and associated static and dynamic barriers, but also due to the growth of biologic therapeutics, and the challenges of delivering and stabilizing these more complex, large molecules. This panel will discuss goals and challenges of delivery, types of delivery systems showing promise for more effective delivery, and the benefits of collaborating in this space.

Moderator:
James Cunningham, PhD
Director, Ocular Drug Delivery, Allergan

Panelists:
Ann Daugherty, PhD
Senior Manager, Drug Delivery, Genentech

Justin Hanes, PhD
Lewis J. Ort Professor, Director, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine

Viral Kansara, PhD
Investigator and Lab Head – Ocular Pharmacology and Drug Delivery, Novartis

Jaymin Shah, PhD
Research Fellow, Pfizer

4:45 pm
Conference Concludes
HOTEL INFORMATION

InterContinental Boston
510 Atlantic Avenue
Boston, MA 02210
617-747-1000

www.intercontinentalboston.com/

For reservations, call 617-747-1000 and ask for the Partnership Opportunities in Drug Delivery group rate.

A contemporary masterpiece, InterContinental® Boston is a landmark of luxury overlooking Boston’s historic waterfront. With its elegant architecture, fine living amenities, and impeccable service, our Boston hotel offers the city’s most captivating 4 Diamond AAA rated hotel experience and has been named one of the ‘Best Hotels in the World’ by Condé Nast Traveler magazine.

REGISTRATION & PRICING

3rd Early Bird - before August 15, 2015 $1,895
4th Early Bird - before September 12, 2015 $1,995
Standard - after September 12, 2015 $2,095

The conference fee includes the program, morning coffee/tea, reception, luncheons, and conference documentation.

To register online:

Discount Programs

Group Registration – Receive a 10% discount off each registration when two or more colleagues from the same company register online.

Large group discounts available.
Please contact Service@tcfllc.org or call 646-350-2580 for any questions on discount rates.

Payment Policy

Payment must be received in full by the event date. All discounts will be applied to the Conference-Only fee (excluding add-ons), cannot be combined with any other offer, and must be paid in full at the time of conference.

Substitution and Cancellation Policy

If you are unable to attend and would like to register a substitute, please email Service@tcfllc.org. Please ask your substitute to provide identification on-site.

If you need to cancel your registration, please note the following policies based on the start date of the event:

Ten or more business days prior: A full refund less the administration fee of $295, or a pass to another event valid for two years from the date of issue.

Less than ten business days prior: A pass to a future event for either yourself or a colleague from the same company valid for two years from the date of issue.

To cancel and receive a refund or pass, please email Service@tcfllc.org or call 646-350-2580.

EXECUTIVE SPONSORS

ASSOCIATE SPONSORS
TECHNOLOGY SPONSORS

Alitus Formulations
Balda Healthcare
BioCorp
BiOASiS
caisson
Ceramisphere
Credence Medsystems
Delta ModTech
Genisphere
LUCIDeon
Insulet Corporation
Innocore Pharmaceuticals
MedPharm
Mercator MedSystems
NanoLogica
Novozymes
OVAL Medical Technologies
PKA SoftTouch Corp
SALVONA
Sensile Medical
SternPharma
Terus Pharma
Unilife
Vectura
ViSci Visual Sciences

SUPPORTING SPONSOR

team.

EXHIBITORS

Buhler Motor
Manta
Phillips Medisize
Polysciences, Inc.
Renishaw
Stress Engineering Services Inc.

SOAPBOX SPONSORS

Cyta Therapeutics
Mirexus
Pi Portal Instruments

MEDIA PARTNERS

10 drugDELIVERY
Big3Bio Boston
CenterWatch
Current Partnering
Drug Development & Delivery
iotechex pharmalicensing
MOD GROUP, LLC
Medical News Today
Pharma Voice

REGISTER at WWW.THECONFERENCEFORUM.ORG or CALL 646-350-2580